HomeCompareAVTE vs EPRT

AVTE vs EPRT: Dividend Comparison 2026

AVTE yields 74.63% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVTE wins by $1.24M in total portfolio value
10 years
AVTE
AVTE
● Live price
74.63%
Share price
$2.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.30M
Annual income
$358,033.82
Full AVTE calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — AVTE vs EPRT

📍 AVTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVTEEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVTE + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVTE pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVTE
Annual income on $10K today (after 15% tax)
$6,343.28/yr
After 10yr DRIP, annual income (after tax)
$304,328.75/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, AVTE beats the other by $293,414.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVTE + EPRT for your $10,000?

AVTE: 50%EPRT: 50%
100% EPRT50/50100% AVTE
Portfolio after 10yr
$682.6K
Annual income
$185,437.27/yr
Blended yield
27.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

AVTE
Analyst Ratings
2
Buy
6
Hold
Consensus: Hold
Price Target
$13.00
+385.1% upside vs current
Range: $2.00 — $35.00
Altman Z
2.1
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVTE buys
0
EPRT buys
0
No recent congressional trades found for AVTE or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVTEEPRT
Forward yield74.63%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1.30M$63.4K
Annual income after 10y$358,033.82$12,840.73
Total dividends collected$1.12M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$13.00$35.50

Year-by-year: AVTE vs EPRT ($10,000, DRIP)

YearAVTE PortfolioAVTE Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$18,163$7,462.69$11,205$505.18+$7.0KAVTE
2$32,102$12,667.52$12,672$682.46+$19.4KAVTE
3$55,273$20,924.46$14,490$930.48+$40.8KAVTE
4$92,813$33,671.17$16,786$1,282.69+$76.0KAVTE
5$152,151$52,841.00$19,753$1,791.56+$132.4KAVTE
6$243,759$80,956.60$23,677$2,541.64+$220.1KAVTE
7$382,036$121,213.91$29,008$3,672.99+$353.0KAVTE
8$586,325$177,546.69$36,463$5,425.08+$549.9KAVTE
9$882,029$254,661.46$47,238$8,221.57+$834.8KAVTE
10$1,301,805$358,033.82$63,385$12,840.73+$1.24MAVTE

AVTE vs EPRT: Complete Analysis 2026

AVTEStock

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Full AVTE Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this AVTE vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVTE vs SCHDAVTE vs JEPIAVTE vs OAVTE vs KOAVTE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.